Evidence map›Paper›PMID 41404475›Full record

ArticleNanoscale advances2026

Nanoparticle-delivered miR-486-5p inhibits H

Ali O Maadelat, Savindi Wehella, Adrianna Douvris, Shireesha Manturthi, Kevin D Burns, Suresh Gadde

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ali O MaadelatDivision of Nephrology, Department of Medicine, University of Ottawa Ottawa ON Canada kburns@toh.ca.ORCID https://orcid.org/0009-0000-5035-6863
Savindi WehellaKidney Research Centre, Ottawa Hospital Research Institute Ottawa ON Canada suresh.gadde@uottawa.ca.ORCID https://orcid.org/0009-0002-0167-7788
Adrianna DouvrisDivision of Nephrology, Department of Medicine, University of Ottawa Ottawa ON Canada kburns@toh.ca.ORCID https://orcid.org/0000-0001-9578-9785
Shireesha ManturthiKidney Research Centre, Ottawa Hospital Research Institute Ottawa ON Canada suresh.gadde@uottawa.ca.ORCID https://orcid.org/0009-0004-3901-8715
Kevin D BurnsDivision of Nephrology, Department of Medicine, University of Ottawa Ottawa ON Canada kburns@toh.ca.ORCID https://orcid.org/0000-0002-1482-5826
Suresh GaddeKidney Research Centre, Ottawa Hospital Research Institute Ottawa ON Canada suresh.gadde@uottawa.ca.ORCID https://orcid.org/0000-0001-9102-3029

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) is a serious condition characterized by a sudden decrease in kidney function, often leading to chronic kidney disease. Current treatment options are limited, necessitating novel therapeutic strategies. We previously showed that microRNA-486-5p (miR-486-5p) protects against AKI by regulating cell death (apoptosis) both

Identifiers

PMID41404475
PMCPMC12703756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.